JC: Epistaxis – The NoPAC trial – Does TXA work?
Is Tranexamic Acid a useful adjunct in the management of epistaxis
JC: Epistaxis – The NoPAC trial – Does TXA work? Read More
SLO10
JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s
In arguably the most important therapeutic news of the pandemic since Dexamethasone, the RECOVERY trial investigators have revealed the initial results on the Tocilizumab arm of the trial showing a
JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s Read More
JC: Canadian TIA risk score. St Emlyn’s
We see a lot of patients in the ED with a history of what sounds very much like a transient ischaemic event (TIA). By definition the patient will have had
JC: Canadian TIA risk score. St Emlyn’s Read More
Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s
Hot on the heels of a terrific pun and blog post about the use of Tocilizumab, capturing all the intrigue, hope and caution with the potential use of this novel therapeutic
Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s Read More
#FOAMed for academics: A primer. St Emlyn’s
This week I’m (virtually) attending the RCEM Research Engagement Day. This annual event combined an academic trainee day (14th) together with a more general day looking at research in a
#FOAMed for academics: A primer. St Emlyn’s Read More
JC: Lopinavir/Ritonavir in the treatment of COVID-19
We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine
JC: Lopinavir/Ritonavir in the treatment of COVID-19 Read More
JC: Azithromycin in patients hospitalised with COVID-19
As we near the end of 2020, it is worth taking a moment to reflect on what a year it has been. At the beginning of the year we were
JC: Azithromycin in patients hospitalised with COVID-19 Read More
JC: Convalescent plasma in COVID 19 patients.
This month the BMJ has published a trial on the use of convalescent plasma in the treatment of admitted patients with COVID-19 (the PLACID trial). Convalescent plasma therapy basically takes
JC: Convalescent plasma in COVID 19 patients. Read More